Choi Pharm Flashcards
Drugs for Acid-Peptic Dz
Agents that reduce intra-gastric acidity:
1. antacids-
NaHCO3, Ca carbonate, Mg hydroxide, Al hydroxide
2. H2 antagonists( -dine)-
cimetidine, ranitidine, nizatidine, famotidine
3. PPI (-zole)-
omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole
Agents that promote mucosal defense:
sucralafate, misoprostol, bismuth compound
Sodium Bicarbonate (baking soda, alka seltzer)
Antacid Can cause: CO2 gas - distention, belching metabolic alkalosis Na - fluid retention
Calcium carbonate (tums)
Antacid Can Cause: -CO2 gas - distention, belching -metabolic alkalosis -Milk alkali syndrome when taken with milk (hypercalcemia, renal insufficiency, metabolic alkalosis)
Magnesium hydroxide
Antacid
Can Cause:
-osmotic diarrheagiven in combo with aluminum hydroxide (maalox)
Aluminum Hydroxide
Antacid
Can Cause:
-constipation
-given in combo with magnesium hydroxide (maalox)
Complications of Antacids
- pts with renal insufficiency should not take long term
- affects absorption of other medications (should not be taken within 2 hours of tetracyclines, fluoroquinolone, itraconazole, and iron)
H2 antagonists
Cimetidine, Ranitidine, Nizatidine, Famotidine
-Best for nocturnal acid secretion
Adverse effects of cimetidine:
- gynecomastia
- inhibits CYP1A2, CYP2C9, CYP2D6, and CYP3A4 (negligible with nizatidine and famotidine)
PPI’s
Omeprazole, Esomeprazole, Lansoprazole, Dexlansoprazole, Rabeprazole, Pantoprazole
- prodrugs
- antagonize meal-stimulated and nocturnal acid secretion
- very short half-life but long duration of action (covalently bind)
- Should be taken 1 hour before meal and for a few days for full affect
Adverse effects:
- decreased B12 levels with prolonged therapy
- increased hip fractures
- life threatening hypomagnesemia with secondary hypocalcemia (black box warning)
- increased risk of both community-acquired respiratory infections and nosocomial pneumonia
- increased risk of enteric infections
- potential problems due to increased serum gastrin
*should not be given with clopidogrel
Triple Therapy
clarithromycin+metronidazole+PPI
Quadruple Therapy
PPI+metronidazole+bismuth cpmd+tetracycline
Sucralafate
Promote Mucosal Defense
- physical barrier and stimulates mucosal PG and HCO3 secretion
- prevention of stress
- related bleeding in critically ill pts
Adverse effects:
-Constipation
Misoprostol
Promote Mucosal Defense
- PGE1 analog
- Reduces histamine-stimulated cAMP production
- stimulates mucous and HCO3 secretion, enhances mucous blood flow
Clinical Uses:
-NSAID-induced ulcers
Adverse effects:
-diarrhea, cramping, abdominal pain, stimulate uterine contrations (C/I in pregnancy)
Bismuth Compunds (pepto bismol)
- create protective layer, may stimulate PG, mucous, HCO3 secretion
- direct antimicrobial effects and binds enterotoxins
Clinical:
- dyspepsia, acute diarrhea, prevention of traveler’s diarrhea
- quadruple therapy
AE:
- black stool and darkening of tongue
- short-term use only, avoid in renal insufficiency
- prolonged usage may lead to bismuth toxicity resulting in ENCEPHALOPATHY (ataxia, HA, confusion, seizures)-salicylate toxicity
Prokinetic Dugs
Cholinomimetics, D2 antagonists, Macrolides
Bethanechol
Cholinomimetic
- stimulates M3
- used in past for tx of gastroparesis
Neostigmine
Cholinomimetic
- AChE inh.
- IV–> hosp. pts with acute large bowel distention (Ogilvie’s syndrome)
AE:
-excessive salivaiton, N/V, diarrhea, bradycardia
Metoclopramide (domperidone in other countries)
D2 antagonist
- D2 receptor inhibits cholinergic stimulation
- tx for diabetic gastroparesis, prevention of vomiting, postpartum lactation stimulation
AE:
- restlessness, drowsiness, insomnia, anxiety, and agitation
- EPS
- Tardive dyskinesia
- elevated prolactin
Erythromycin (as prokinetic)
Stimulates motilin receptors causing a MMC
-IV for gastroparesis, gastric emptying of blood in acute upper GI hemorrhage before endoscopy
Laxatives
- bulk forming
- stool softeners
- osmotic laxatives
- stimulant laxatives
- Cl channel activator
- opiod receptor antagonists
- 5HT4 agonists
- Guanylate cyclase C agents